http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Kim, Bohyun,Park, Seong Ho,Hong, Gil-Sun,Lee, Ju Hee,Lee, Jong Seok,Kim, Hyun Jin,Kim, Ah Young,Ha, Hyun Kwon Springer International 2015 European radiology Vol.25 No.6
<P>We aimed to compare iohexol vs. diatrizoate as fecal/fluid tagging agents for computed tomography colonography (CTC) regarding examination quality.</P>
Kim, Bohyun,Park, Seong Ho,Pickhardt, Perry J,Lee, Seung Soo,Ahn, Soyeon,Kim, Jihun,Kim, Jin Cheon,Yu, Chang Sik,Yang, Suk-Kyun,Kim, Ah Young,Ha, Hyun Kwon Radiological Society of North America 2014 Radiology Vol. No.
<P>To determine the postoperative incidence of adenomatous neoplasia in the colon proximal to an occlusive colorectal cancer where preoperative computed tomographic (CT) colonography findings were normal.</P>
Clinical Significance of CLDN18.2 Expression in Metastatic Diffuse-Type Gastric Cancer
Kim, Seo Ree,Shin, Kabsoo,Park, Jae Myung,Lee, Han Hong,Song, Kyo Yong,Lee, Sung Hak,Kim, Bohyun,Kim, Sang-Yeob,Seo, Junyoung,Kim, Jeong-Oh,Roh, Sang-Young,Kim, In-Ho The Korean Gastric Cancer Association 2020 Journal of gastric cancer Vol.20 No.4
Purpose: Isoform 2 of tight junction protein claudin-18 (CLDN18.2) is a potential target for gastric cancer treatment. A treatment targeting CLDN18.2 has shown promising results in gastric cancer. We investigated the clinical significance of CLDN18.2 and other cell-adherens junction molecules (Rho GTPase-activating protein [RhoGAP] and E-cadherin) in metastatic diffuse-type gastric cancer (mDGC). Materials and Methods: We evaluated CLDN18.2, RhoGAP, and E-cadherin expression using two-plex immunofluorescence and quantitative data analysis of H-scores of 77 consecutive mDGC patients who received first-line platinum-based chemotherapy between March 2015 and February 2017. Results: CLDN18.2 and E-cadherin expression was significantly lower in patients with peritoneal metastasis (PM) than those without PM at the time of diagnosis (P=0.010 and 0.013, respectively), whereas it was significantly higher in patients who never developed PM from diagnosis to death than in those who did (P=0.001 and 0.003, respectively). Meanwhile, CLDN18.2 and E-cadherin expression levels were significantly higher in patients with bone metastasis than in those without bone metastasis (P=0.010 and 0.001, respectively). Moreover, we identified a positive correlation between the expression of CLDN18.2 and E-cadherin (P<0.001), RhoGAP and CLDN18.2 (P=0.004), and RhoGAP and E-cadherin (P=0.001). Conversely, CLDN18.2, RhoGAP, and E-cadherin expression was not associated with chemotherapy response and survival. Conclusions: CLDN18.2 expression was reduced in patients with PM but significantly intact in those with bone metastasis. Furthermore, CLDN18.2 expression was positively correlated with other adherens junction molecules, which is clinically associated with mDGC and PM pathogenesis.
Monodisperse Microshell Structured Gelatin Microparticles for Temporary Chemoembolization
Kim, Bohyun,Han, Sang Woo,Choi, Song-Ee,Yim, DaBin,Kim, Jong-Ho,Wyss, Hans M.,Kim, Jin Woong American Chemical Society 2018 Biomacromolecules Vol.19 No.2
<P>Embolization is a nonsurgical, minimally invasive procedure that deliberately blocks a blood vessel. Although several embolic particles have been commercialized, their much wider applications have been hampered owing mainly to particle size variation and uncontrollable degradation kinetics. Herein we introduce a microfluidic approach to fabricate highly monodisperse gelatin microparticles (GMPs) with a microshell structure. For this purpose, we fabricate uniform gelatin emulsion precursors using a microfluidic technique and consecutively cross-link them by inbound diffusion of glutaraldehyde from the oil continuous phase to the suspending gelatin precursor droplets. A model micromechanic study, carried out in an artificial blood vessel, demonstrates that the extraordinary degradation kinetics of the GMPs, which stems from the microshell structure, enables controlled rupturing while exhibiting drug release under temporary chemoembolic conditions</P>
( Bohyun Kim ),( Soon Sun Kim ),( Sung Won Cho ),( Jae Youn Cheong ),( Jimi Huh ),( Jai Keun Kim ),( Jei Hee Lee ),( Hye Ri Ahn ),( Hyo Jung Cho ) 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Aims: Liver stiffness (LS) is an emerging imaging-based prognostic biomarker for patients with chronic liver disease. We investigated whether LS quantified using magnetic resonance elastography (MRE) could predict the prognosis of advanced hepatocellular carcinoma (HCC) patients treated with sorafenib. Methods: We selected 50 sorafenib-treated advanced HCC patients who underwent MRE within 3 months before drug administration from a prospectively maintained cohort of chronic liver disease patients, according to the inclusion and exclusion criteria. Univariate and multivariate analyses were performed to evaluate the prognostic role of laboratory data, tumor characteristics, and MRE-assessed LS for overall survival (OS), progression-free survival (PFS), and significant liver injury (≥grade 3) after sorafenib administration. Results: High MRE-assessed LS was significantly associated with poor OS (kPa; hazard ratio [HR], 1.54; 95% confidence interval [CI], 1.23-1.92; P<0.001) as well as higher serum alpha-fetoprotein (AFP, ≥400 ng/mL) and advanced tumor stage (modified Union for International Cancer Control [mUICC] IVb). Higher MRE-assessed LS was also significantly associated with the development of significant liver injury after sorafenib administration (kPa; HR, 1.62; 95% CI, 1.21-2.17; P=0.001). PFS analysis identified higher serum AFP (≥400 ng/mL) and advanced tumor stage (modified UICC IVb) as significant risk factors for early disease progression, whereas LS was not associated with PFS. Conclusions: Higher MRE-assessed LS is a potential biomarker for predicting poor OS and significant liver injury in advanced HCC patients treated with sorafenib.
PUBLIC UNION EFFECTS ON TOTAL COMPENSATION AND EMPLOYMENT LEVELS
KIM, BOHYUN 東國大學校 1990 論文集 Vol.29 No.-
본 논문은 공무원 보수·고용수준의 결정요인에 관한 연구이다. 특히 공무원의 노조활동이 공무원의 보수와 고용수준을 결정하는데 미치는 영향에 관하여 분석하였다. 대부분의 실증적 연구논문들이 원용하는 고전적 분석모형인 대표적 유권자 모델(median voter model)에서 탈피하여 보다 현실적인 접근 방법으로 일종의 투표 극대화 모형을 구축하였다. 이 새로 제시된 분석모형을 토대로 이단계 최소 자승방법(two-stage least squares)을 사용하여 유니온이즘(unionism)이 공무원 보수나 고용수준에 미치는 영향을 조사한 실증적연구 결과, 기존의 연구 결과보다 2-3배가 크게 나타났다.
Kim Dae Hwan,Chun So Young,이은혜,Kim Bomi,Yoon BoHyun,Gil Haejung,Han Man-Hoon,Ha Yun-Sok,Lee Jun Nyung,Kwon Tae Gyun,김범수,장병익 한국조직공학과 재생의학회 2021 조직공학과 재생의학 Vol.18 No.3
BACKGROUND: High-fat diet-induced obesity is one of the major cause of chronic renal failure. This obesity-related renal failure is mainly caused by inflammatory processes. However, the role of the major anti-inflammatory cytokine interleukin (IL)-10 has not been researched intensively. METHODS: To evaluate the effect of IL-10 deficiency on obesity-related renal failure, the in vivo study was carried with four animal groups; (1) Low-fat dieted C57BL/6 mice, (2) Low-fat dieted IL-10 knockout (KO) mice, (3) High‐fat dieted C57BL/6 mice and (4) High‐fat dieted IL-10 KO mice group. The analysis was carried with blood/urine chemistry, H&E, Oil-Red-O, periodic acid-Schiff and Masson’s trichrome staining immunohistochemistry and real-time PCR methods. RESULTS: At week 12, high‐fat dieted IL-10 KO mice showed 1) severe lipid accumulation in kidneys, cholesterol elevation (in total, serum kidney) and low-density lipoprotein increasion through the SCAP-SREBP2-LDLr pathway; (2) serious histopathologic alterations showing glomerulosclerosis, tubulointerstitial fibrosis and immune cell infiltration; (3) increased pro‐inflammatory cytokines and chemokines expression; (4) enhanced renal fibrosis; and (5) serious functional failure with high serum creatinine and BUN and proteinuria excretion compared to other groups. CONCLUSION: IL-10 deficiency aggravates renal inflammation, fibrosis and functional failure in high-fat dieted obese mice, thus IL-10 therapy could be applied to obesity-related chronic renal failure. BACKGROUND: High-fat diet-induced obesity is one of the major cause of chronic renal failure. This obesity-related renal failure is mainly caused by inflammatory processes. However, the role of the major anti-inflammatory cytokine interleukin (IL)-10 has not been researched intensively. METHODS: To evaluate the effect of IL-10 deficiency on obesity-related renal failure, the in vivo study was carried with four animal groups; (1) Low-fat dieted C57BL/6 mice, (2) Low-fat dieted IL-10 knockout (KO) mice, (3) High‐fat dieted C57BL/6 mice and (4) High‐fat dieted IL-10 KO mice group. The analysis was carried with blood/urine chemistry, H&E, Oil-Red-O, periodic acid-Schiff and Masson’s trichrome staining immunohistochemistry and real-time PCR methods. RESULTS: At week 12, high‐fat dieted IL-10 KO mice showed 1) severe lipid accumulation in kidneys, cholesterol elevation (in total, serum kidney) and low-density lipoprotein increasion through the SCAP-SREBP2-LDLr pathway; (2) serious histopathologic alterations showing glomerulosclerosis, tubulointerstitial fibrosis and immune cell infiltration; (3) increased pro‐inflammatory cytokines and chemokines expression; (4) enhanced renal fibrosis; and (5) serious functional failure with high serum creatinine and BUN and proteinuria excretion compared to other groups. CONCLUSION: IL-10 deficiency aggravates renal inflammation, fibrosis and functional failure in high-fat dieted obese mice, thus IL-10 therapy could be applied to obesity-related chronic renal failure.
Liver Imaging : Portal flow steal after liver transplantation
( Bohyun Kim ),( Kyoung Won Kim ),( Gi-won Song ),( Sung-gyu Lee ) 대한간학회 2015 Clinical and Molecular Hepatology(대한간학회지) Vol.21 No.3
Portal flow steal occasionally persists even after the liver transplantation, which may reduce the portal flow and thus threaten the patients’ outcome. Therefore, pre- and peri-operative detection of portal steal phenomenon requiring radiological or surgical interruption is essential for the liver transplantation candidates as well as for the recipients. (Clin Mol Hepatol 2015;21:314-317)